SCHEMBL14725170

SCHEMBL14725170

CC(C)c1cnn(CCN2CCN(C)CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.40
KDM5B Q9UGL1 1/20 0.36
FGFR3 P22607 1/20 0.35
GAA P10253 1/20 0.35
PAICS P22234 1/20 0.35
LMNA P02545 2/20 0.34
TLR7 Q9NYK1 1/20 0.33
HTR6 P50406 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
KDM1A O60341 1/20 0.33
S1PR1 P21453 1/20 0.33
HRH4 Q9H3N8 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
POLB P06746 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14725169 0.89 KDM5B (0.35) KDM5BGAALMNAHTR6KDM1A
SCHEMBL17789616 0.88 MEN1 (0.43) HTR7KDM5BLMNAALDH1A1MEN1
SCHEMBL10141504 0.87 MEN1 (0.42) KDM5BLMNAACHEALDH1A1MEN1
SCHEMBL18930365 0.86 ALDH1A1 (0.38) HTR7KDM5BFGFR3GAAPAICS
SCHEMBL12090079 0.85 KDM5B (0.47) KDM5BFGFR3TLR7ACHES1PR1
SCHEMBL15133217 0.84 KDM2B (0.42) KDM5BACHEALDH1A1MEN1KMT2A
SCHEMBL18925949 0.84 FGFR3 (0.40) KDM5BFGFR3PAICSDRD3KDM1A
SCHEMBL22102130 0.83 TLR7 (0.33) HTR7KDM5BFGFR3PAICSTLR7
SCHEMBL12285332 0.79 NOS3 (0.38) HTR7FGFR3GAAPAICSLMNA
SCHEMBL18948340 0.78 LTA4H (0.36) KDM5BS1PR1ALDH1A1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 WO disclosed
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
WO-2021003314-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2021-01-07 WO disclosed
US-20200190095-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF ABS DEVELOPMENT 1, INC. 2020-06-18 US disclosed
US-20190092779-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF Libertas Bio, Inc. 2019-03-28 US disclosed
US-20190070182-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER ASANA BIOSCIENCES, LLC 2019-03-07 US disclosed
US-20170157126-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER ASANA BIOSCIENCES, LLC (US) 2017-06-08 US disclosed
US-20160257691-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF Libertas Bio, Inc. 2016-09-08 US disclosed
US-9382277-B2 Pyrimido-pyridazinone compounds and methods of use thereof ASANA BIOSCIENCES, LLC (US) 2016-07-05 US disclosed
US-9150578-B2 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
US-9150578-B2 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
US-8962596-B2 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases ARRAY BIOPHARMA INC. (US) 2015-02-24 US disclosed
US-8962596-B2 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases ARRAY BIOPHARMA INC. (US) 2015-02-24 US disclosed
US-20140228349-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES ARRAY BIOPHARMA, INC. 2014-08-14 US disclosed
US-20140221315-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF ENDO PHARMACEUTICALS INC. (US) 2014-08-07 US disclosed
US-8729079-B2 Pyrimido-pyridazinone compounds and methods of use thereof ENDO PHARMACEUTICALS INC. (US) 2014-05-20 US disclosed
US-20130190305-A1 NEW 5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLINES AS IGF-1R/IR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-25 US disclosed
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2013-05-23 US disclosed
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2013-05-23 US disclosed
US-20130053346-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF ENDO PHARMACEUTICALS INC (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070182-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER MKI67, DPYD, TYMP HTR7 2107/4885KDM5B 1906/4885FGFR3 643/4885
US-20160257691-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS HTR7 1526/4885KDM5B 799/4885FGFR3 2290/4885
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES JAK1, JAK3, JAK2 HTR7 1710/4885KDM5B 1149/4885FGFR3 513/4885
US-20140228349-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES JAK1, JAK3, JAK2 HTR7 1509/4885KDM5B 1575/4885FGFR3 665/4885
US-20170157126-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER MKI67, DPYD, TYMP HTR7 2107/4885KDM5B 1906/4885FGFR3 643/4885
US-20190092779-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS HTR7 1526/4885KDM5B 799/4885FGFR3 2290/4885
US-20200190095-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS HTR7 1526/4885KDM5B 799/4885FGFR3 2290/4885
US-20130190305-A1 NEW 5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLINES AS IGF-1R/IR INHIBITORS IGF1R, IGFBP1, INSR HTR7 664/4885KDM5B 3025/4885FGFR3 52/4885
US-20140221315-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS HTR7 1526/4885KDM5B 799/4885FGFR3 2290/4885
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases MAP3K1, MAP3K3, MAP3K2 HTR7 3103/4885KDM5B 1793/4885FGFR3 361/4885
US-20130053346-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS HTR7 1526/4885KDM5B 799/4885FGFR3 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.